Showing posts with label Clinical Trial. Show all posts
Showing posts with label Clinical Trial. Show all posts

Sunday, November 29, 2009

Scientists find link between gut microbiota, diet, and weight gain.

Moral of the story: What you eat matters. A lot. The link between diet and weight is rather complicated and taking out fats and sugars can help to change the fauna of your stomach to help you lose weight. Chewing gum and breastfeeding help shed pounds too.

Source: AMA Morning Rounds 11/12/09

Scientists find link between gut microbiota, diet, and weight gain.

The Los Angeles Times (11/12, Maugh) reported, "A high-fat, high-sugar diet does more than pump calories into your body. It also alters the composition of bacteria in your intestines, making it easier to gain weight and harder to lose it," according to a new paper in Science Translational Medicine. What's more, the "changeover can happen in as little as 24 hours."

Technically known "as the gut microbiota," intestinal "microbes perform a vast range of vital functions, including helping to regulate the calories the body obtains from food and stores as fat," according to Time (11/12, Park). Through earlier experiments, however, Washington University researchers found that the "gut microbiota of obese mice...have significantly more of one main type of bacteria called Firmicutes, and fewer of another kind called Bacteroidetes (both types populate human guts as well); in normal mice, the distribution is the opposite." With that in mind, the team devised a new study in which human microbiota was used "to colonize mice guts." The rodents were then fed "equivalents of typical human diets to see how their microbes -- and their weight -- might change."

Lead investigator Dr. Jeffrey I. Gordon told HealthDay (11/11, Gordon) that when his team "switched these humanized animals [from a low-fat] to a junk-food diet, high in fat with lots of simple sugars, the structure of the microbial community changed dramatically and very rapidly." What's more, the mice "became obese on Western diets." Investigators also discovered that "the microbiota passes from generation to generation."

Study points to chewing gum as weight loss aid. The Washington Post (11/11, Huget) reports that for anybody trying to lose weight, "taking up gum-chewing might not be a bad idea," as "there's actually a bit of scientific evidence showing that chewing gum helps fight fat in a number of ways." The research, sponsored by the Wrigley Science Institute, has suggested "that chewing gum may help reduce cravings, particularly for sweet snacks, and spur people to cut their daily intake by about 50 calories." The findings were presented at the annual scientific meeting of the Obesity Society last month, and "showed that gum-chewing people consumed 67 fewer calories at lunch and didn't compensate by eating more later in the day."

Breastfeeding's effect on postpartum weight discussed. The New York Times (11/12, E3, Louis) reports, "That breastfeeding gives mothers an edge shedding baby weight has long been suspected." A Danish study published last year showed that "the more a mother breast-feeds, the less weight she retains six months after birth." But, other research has shown that "breast-feeders don't necessarily shed fat quicker than women who feed their newborns formula." Meanwhile, "a small double-blind randomized study conducted at Cincinnati Children's Hospital Medical Center found that non-lactating women lost more body fat than lactating women at six months, and at a faster rate." Still, "others suggest that women who view breast-feeding as a dieting tool may have 'deeper body issues.'" One expert said "she was troubled by our cultural preoccupation with postpartum weight."

Vaccines against cocaine, nicotine addiction modeled after infectious diseases research.

Moral of the story: A really cool idea that may just help people quit smoking, completely.

Source: AMA Morning Rounds 11/16/09

Vaccines against cocaine, nicotine addiction modeled after infectious diseases research.

USA Today (11/16, Rubin) reported, "Researchers are investigating whether the same approach used to prevent infectious diseases could treat addictions." Nicotine and cocaine molecules "are so tiny that they easily pass from the bloodstream into the brain." A vaccine, however, can stimulate the production of antibodies that "bind with the molecules," making the combo "far too large." No such vaccines are "on the market, but in late September, NIDA released a $10 million stimulus grant to Nabi Pharmaceuticals to help pay for the first Phase III trial...of a smoking-cessation vaccine." And, a paper published in the Archives of General Psychiatry carried successful "results of a cocaine vaccine study." The study's lead author, however, pointed out that "no company is interested in developing a cocaine vaccine because of liability concerns and the assumption it wouldn't be nearly as profitable as a nicotine vaccine."

Depression may take as many years off life as smoking.

Moral of the story: Mental illnesses are serious threats to long-term health

Source: AMA Morning Rounds 11/24/09

Depression may take as many years off life as smoking.

HealthDay (11/23, Dotinga) reported that, according to a study published in the British Journal of Psychiatry, "being depressed might take as many years off your life as smoking does." After "analyzing death records and a survey of more than 60,000 people," researchers at King's College London found that "during the four years after the survey, the death rate was higher among those who'd appeared to be depressed, based on the survey findings, than among the others," with the "increase...about as high as that among smokers." Notably, the investigators also found that "a combination of depression and anxiety appears to be better for longevity than just depression."

On Mammography — More Agreement Than Disagreement

Moral of the story: Not much has changed, there is just more emphasis on the risks for the age group 40-50 and that the screen should be done every other year.

Published at www.nejm.org November 25, 2009 (10.1056/NEJMp0911288)

On Mammography — More Agreement Than Disagreement
Ann H. Partridge, M.D., M.P.H., and Eric P. Winer, M.D.

Friday, November 20, 2009

Spray-on anesthetic helps delay ejaculation.

Moral of the story: One of those awkward doorknob questions just got a better answer.

Source: AMA Morning Rounds 11/20/09

Bloomberg News (11/20, Matsuyama) reports, "A spray-on treatment for premature ejaculation may prolong sexual intercourse by as much as five times." In fact, the drug, known as PSD502, "delayed orgasm by an average of 108 seconds" after one month of treatment, according to a 256-patient trial conducted in Canada, Poland, and the US.

The work may benefit the estimated "one in three US men ages 18 to 59" who have dealt with the problem at one time or another, according to the Los Angeles Times (11/19, Maugh) "Booster Shots" blog. That's "about twice as many as those who suffer from erectile dysfunction." Indeed, "some antidepressant-like drugs, such as dapoxetine, have been approved in a few countries to treat the condition, but the Food and Drug Administration rejected it because of long-term side effects." And while "some physicians prescribe anesthetic creams like EMLA cream...off-label," they "require 45 minutes to work."

Now, researchers at the University of California-San Francisco may have stumbled upon a solution. According to WebMD (11/19, DeNoon), the spray "contains the anesthetics lidocaine and prilocaine," but it "doesn't deaden feeling, thanks to an ingredient in the spray that allows it to rapidly penetrate the skin." What's more, it "seems safe for men's female sex partners," as "only about 0.5% of female partners report decreased feeling in the vagina."

In light of those findings, HealthDay (11/19, Preidt) pointed out, "Sciele Pharma plans to seek US Food and Drug Administration approval of the spray." Reuters (11/20), the UK's Telegraph (11/19), and the UK's Press Association (11/19) also covered the story.

Friday, October 30, 2009

Comparison of Liquid-Based Cytology With Conventional Cytology for Detection of Cervical Cancer Precursors

Moral of the story: Conventional PAP smear is just as good (but FAR cheaper) than liquid cytology.

Source: JAMA. 2009;302(16):1757-1764.

Comparison of Liquid-Based Cytology With Conventional Cytology for Detection of Cervical Cancer Precursors

A Randomized Controlled Trial

Albertus G. Siebers, MSc; Paul J. J. M. Klinkhamer, MD; Johanna M. M. Grefte, MD, PhD; Leon F. A. G. Massuger, MD, PhD; Judith E. M. Vedder; Angelique Beijers-Broos; Johan Bulten, MD, PhD; Marc Arbyn, MD, MSc, DrTMH

Context Liquid-based cytology has been developed as an alternative for conventional cervical cytology. Despite numerous studies and systematic reviews, controversy remains about its diagnostic accuracy.

Objective To assess the performance of liquid-based cytology compared with conventional cytology in terms of detection of histologically confirmed cervical intraepithelial neoplasia (CIN).

Design, Setting, and Participants Cluster randomized controlled trial involving 89 784 women aged 30 to 60 years participating in the Dutch cervical screening program at 246 family practices. One hundred twenty-two practices were assigned to use liquid-based cytology and screened 49 222 patients and 124 practices were assigned to use the conventional Papanicolaou (Pap) test and screened 40 562 patients between April 2004 and July 1, 2006. Patients were followed up for 18 months through January 31, 2008.

Intervention Screening for CIN using liquid-based cytology or conventional papanicolaou (Pap) test and the blinded review of all follow-up of screen-positive women (blinded to the type of cytology and the initial result).

Main Outcome Measures Intention-to-treat and per-protocol analysis of the detection rates of and positive predictive values for histologically verified CIN in both cytology systems. Outcomes are presented as crude and adjusted rate ratios (adjustment for age, urbanization, study site, and period).

Results The adjusted detection rate ratios for CIN grade 1+ was 1.01 (95% confidence interval [CI], 0.85-1.19); for CIN grade 2+, 1.00 (95% CI, 0.84-1.20); for CIN grade 3+, 1.05 (95% CI, 0.86-1.29); and for carcinoma, 1.69 (95% CI, 0.96-2.99). The adjusted positive predictive value (PPV) ratios, considered at several cytological cutoffs and for various outcomes of CIN did not differ significantly from unity.

Conclusion This study indicates that liquid-based cytology does not perform better than conventional Pap tests in terms of relative sensitivity and PPV for detection of cervical cancer precursors.

Trial Registration trialregister.nl Identifier: NTR1032


Author Affiliations: Departments of Pathology (Mr Siebers, Drs Grefte and Bulten, and Ms Vedder) and Obstetrics and Gynaecology (Dr Massuger), Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; Laboratory of Pathology, PAMM Laboratories, Eindhoven, the Netherlands (Dr Klinkhamer and Ms Beijers-Broos); and Scientific Institute of Public Health, Brussels, Belgium (Dr Arbyn).

Friday, June 26, 2009

Longer life linked to specific foods in Mediterranean diet

Moral of the story: More evidence that certains foods in the mediterranean diet are really good for you. Note the information on fish, meat, cereals and dairy.

An article summary from the British Medical Journal:

(2) Longer life linked to specific foods in Mediterranean diet(Research: Anatomy of the health effects of the Mediterranean diet, The Greek EPIC prospective cohort study)
http://www.bmj.com/cgi/doi/10.1136/bmj.b2175
Some food groups in the Mediterranean diet are more important than others in promoting health and longer life according to new research published on bmj.com today.
Eating more vegetables, fruits, nuts, pulses and olive oil, and drinking moderate amounts of alcohol, while not consuming a lot of meat or excessive amounts of alcohol is linked to people living longer.
However, the study also claims, that following a Mediterranean diet high in fish, seafood and cereals and low in dairy products were not indicators of longevity.
While several studies have concluded that the Mediterranean diet improves chances of living longer, this is the first to investigate the importance of individual components of the diet.
Professor Dimitrios Trichopoulos at the Harvard School of Public Health explains that they have surveyed over 23,000 men and women who were participants in the Greek segment of the European Prospective Investigation into Cancer and Nutrition (EPIC).
Participants were given dietary and lifestyle questionnaires when they enrolled onto the study and they were subsequently followed up for around 8.5 years with interviews. Their diets were rated from 0 to 10 based on the level of conformity to a traditional Mediterranean diet.
As part of the interview process, participants were also asked about their smoking status, levels of physical activity and whether they had ever been diagnosed with cancer, diabetes and heart disease.

The authors maintain that when high intake of vegetables, low intake of meat or moderate alcohol intake were excluded from the rating system, the benefits of following a Mediterranean diet were substantially reduced. They also note that there are clear benefits in combining several of the key components, for example high consumption of vegetables and olive oil.
Professor Trichopoulou, lead author of the study, concludes that the main reasons why the Mediterranean diet can lead to living longer are moderate consumption of ethanol (mostly in the form of wine during meals, as traditionally done in the Mediterranean countries), low consumption of meat and meat products, and high consumption of vegetables, fruits and nuts, olive oil and legumes.
Contacts: Professor Dimitrios Trichopoulos, Harvard School of Public Health, Boston, USAEmail: dtrichop@hsph.harvard.edu OrProfessor Antonia Trichopoulou, University of Athens Medical School, Athens, GreeceEmail: http://www.bmj.com/cgi/doi/10.1136/bmj.b2337

Wednesday, May 20, 2009

Study finds volunteering decreases mortality risk among retired

Moral of the story: Start volunteering, it may save your life. This study looks at retirees and found volunteering has bidirectional affects with health. Not only is volunteering a sign of good health, it also improves health. Get yourself, your parents or your grandparents out there volunteering.

Study finds volunteering decreases mortality risk among retired

The Advisory Board Company
05/19/2009

Retirees older than age 65 who volunteer have a lower mortality risk than their non-volunteering peers, according to a study presented earlier this month at the American Geriatrics Society’s annual meeting in Chicago. Although previous research identified a link between volunteering and lower mortality rates, such studies involved individuals born before 1920 and failed to adjust the results for possible confounders, such as socioeconomic status and chronic health conditions. To assess the relationship when accounting for those variables, researchers from the University of California-San Francisco and Montefiore Medical Center examined 6,360 retired men and women older than age 65 who were enrolled in the Health and Retirement Study—considered representative of all U.S. adults—in 2002. Study subjects had an average age of 78, and 60% were female. Examining participants’ volunteerism patterns, the researchers found that 12% of participants who volunteered died, compared with 26% of non-volunteers. After adjusting the data for participants’ demographics, socioeconomic status, chronic health conditions, geriatric syndromes, functional limitations, self-rated health, depression, and cognition, the researchers found that the link “wasn’t as strong, but still existed.” Commenting on the study, one researcher notes that volunteering may be associated with self-efficacy—a belief in one’s own abilities to accomplish tasks—which helps individuals remain engaged in a healthy and active lifestyle (Gordon, HealthDay, 5/8).

Thursday, April 16, 2009

heart-health benefits from a Mediterranean diet

Moral of the story: Time and again the Mediterranean diet is proven to be a healthy eating option. This meta-analysis (aggregates all the previous studies) finalizes the debate, if there ever was one. Time to break out the fish and olives, but remember to eat sustainably, we want everyone to be able to enjoy these health benefits many years from now.

Heartwire: Prevention
Meta-analysis supports heart-health benefits from a Mediterranean diet
April 16, 2009 | Marlene Busko

Hamilton, ON - Strong evidence supports the protective effect of a Mediterranean diet on risk of CHD, and overall diet pattern appears more important than individual foods [1].

These findings, from a review of close to 200 studies, are published in the April 13, 2009 issue of the Archives of Internal Medicine.

"We found strong evidence that a 'Western' diet—which is high in processed meats, red meats, butter, eggs, refined grains, and high-fat dairy products—is associated with an increased risk of CAD, so we could say [to patients]: 'You should consume less of those types of foods and gravitate more toward a "prudent" diet or a Mediterranean diet, which are both high in fruits and vegetables, legumes, whole grains, and fish,' " senior author Dr Sonia Anand (McMaster University, Hamilton, ON) told heartwire.

Although this message is not really new, what is new is the way that this review assessed the strength of the evidence, she noted.

The study also found strong evidence of increased CHD risk from consuming trans-fatty acids and foods with a high glycemic index such as white potatoes, sugar, white rice, and white bread.

Physicians should advise patients: "Lower your trans-fats, lower your saturated fats, but also watch for some of these simple carbohydrates, because they can have adverse effects as well,'' said Anand.


Diet dilemma

The relationship between diet and CHD has been studied for decades, yet there is still some confusion about which foods or diets are best, since cohort studies and randomized controlled trials have often produced discrepant results, the researchers write.

To examine the strength of the evidence supporting a causal link between diet and CHD, the researchers reviewed 146 prospective cohort studies and 43 randomized controlled trials (RCTs).

Studies were scored on how well they met four criteria of strength, consistency, temporality, and coherence. A score of 4 was considered strong evidence of a cause-and-effect relationship between dietary exposure and disease.


Dietary pattern vs single food

In the cohort studies, a Mediterranean diet—characterized by higher intake of vegetables, legumes, fruits, nuts, whole grains, cheese or yogurt, fish, and monounsaturated as opposed to saturated fatty acids—and a "prudent diet"—characterized by high intake of vegetables, fruit, legumes, whole grains, fish, and other seafood—were each associated with significantly lower risk of CHD. Similarly, strong evidence supported the benefits from monounsaturated fatty acids and foods such as vegetables and nuts and the harm from trans-fatty acids and foods with a high glycemic index.

In the RCTs, however, only the Mediterranean diet was strongly linked to risk of CHD.

"Our findings support the strategy of investigating dietary patterns in cohort studies and RCTs for common and chronic complex diseases such as CHD," the researchers write.


Study reinforces heart-healthy diet

Commenting on the results for heartwire, Dr Robert Eckel (University of Colorado, Denver) said that the study confirms previous notions about what a heart-healthy diet is all about.

It's not a matter of good foods and bad foods. It's what the overall quality of the diet is.

"I think cardiologists need to increasingly make lifestyle-related issues an important part of their practice," he added. "This is another article reinforcing that a heart-healthy diet contains certain constituents and avoids certain constituents."

Concurring with the study authors, he noted: "Overall, the dietary pattern is what needs to be emphasized. It's not a matter of good foods and bad foods. It's what the overall quality of the diet is. The Western pattern is high in saturated fat, trans-fat, and cholesterol, whereas a Mediterranean diet and 'prudent' diet include more monounsaturated or polyunsaturated fats, and there is more fish consumption."

No financial disclosures were reported.
Source
  1. Mente A, de Koning L, Shannon HS, et al. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med 2009; 169:659-669.

Wednesday, March 25, 2009

Obesity Fact or Fiction?

Moral of the story: There is a ton of information out there about obesity and being overweight. Some of it is misinformation, get the facts below. If you want links to the articles click here.

Nature: Obesity
Factor or Fiction?

FICTION: Children who are tall but heavy will eventually grow into their weight and have a healthier BMI as they age.

The Interaction of Childhood Height and Childhood BMI in the Prediction of Young Adult BMI
Steven D. Stovitz, Mark A. Pereira, Gabriela Vazquez, Leslie A. Lytle and John H. Himes
Obesity advance online publication; July 24, 2008; doi:10.1038/oby.2008.359

FACT: An estimated 17% of children and adolescents ages 2-19 years are overweight*.
*Results from 2003-2004 National Health and Nutrition Examination Survey (NHANES)

School-based Obesity Prevention Programs: An Evidence-based Review
Jonathan A. Kropski, Paul H. Keckley and Gordon L. Jensen
Obesity 16; 1009-1018; doi:10.1038/oby.2008.29

Four-year Follow-up of School-based Intervention on Overweight Children: The KOPS Study
Sandra Plachta-Danielzik, Svenja Pust, Inga Asbeck, Mareike Czerwinski-Mast, Kristina Langnäse, Carina Fischer, Anja Bosy-Westphal, Peter Kriwy and Manfred J. Müller
Obesity 15; 3159-3169; doi:10.1038/oby.2007.376

FACT: Studies have reported that up to 60% of individuals with schizophrenia and 68% of those with bipolar disorder are overweight/obese.

Impact of Obesity on Health-related Quality of Life in Schizophrenia and Bipolar Disorder
Ronette L. Kolotkin, Patricia K. Corey-Lisle, Ross D. Crosby, Jodi M. Swanson, Anne V. Tuomari, Gilbert J. L'Italien and James E. Mitchell
Obesity 16; 749-754; doi:10.1038/oby.2007.133

FICTION: Being overweight has little or no impact on calling in sick to work or school.

Relative Weight and Sickness Absence
Mikko Laaksonen, Kustaa Piha and Sirpa Sarlio-Lähteenkorva
Obesity 15; 465-472; doi:10.1038/oby.2007.55

The Relationship Between Relative Weight and School Attendance Among Elementary Schoolchildren
Andrew B. Geier, Gary D. Foster, Leslie G. Womble, Jackie McLaughlin, Kelley E. Borradaile, Joan Nachmani, Sandy Sherman, Shiriki Kumanyika, Justine Shults
Obesity 15; 2157-2161; doi:10.1038/oby.2007.256

FACT: Moving? Be careful where you settle down - unpacking your belongings in a new location may pack on extra pounds.

Neighborhood Risk Factors for Obesity
Russ P. Lopez
Obesity 15; 2111-2119; doi:10.1038/oby.2007.251

FACT: Lack of seatbelt use can be added to the list of risk factors associated with obesity.

BMI and Seatbelt Use
David G. Schlundt, Nathaniel C. Briggs, Stephania T. Miller, Carlotta M. Arthur and Irwin A. Goldzweig
Obesity 15; 2541-2545; doi:10.1038/oby.2007.303

FICTION: Women in their first year of college have a 48% chance of gaining the "freshman 15."

Freshman 15: Fact or Fiction?
Michelle L. Morrow, Kristiann C. Heesch, Mary K. Dinger, Holly R. Hull, Allen W. Kneehans, David A. Fields
Obesity 14; 1438-1443; doi:10.1038/oby.2006.163

FACT: Listen to your heart. If you're obese, you could be at risk of developing cardiovascular disease and diabetes.

Relationship of Metabolic Risk Factors and Development of Cardiovascular Disease and Diabetes
Steven M. Haffner
Obesity 14; 121S-127S; doi:10.1038/oby.2006.291

Childhood Behavioral Problems Predict Young Adults' BMI and Obesity

Moral of the story: Behavioral problems predict weight gain later in life. Simply be aware of this connection and monitor weight carefully in children with behavioral problems. Make sure they exercise and eat healthy. If you have a diagnosed behavior issue, get on that treadmill!

Epidemiology

Obesity (2009) 17 4, 761–766. doi:10.1038/oby.2008.594

Childhood Behavioral Problems Predict Young Adults' BMI and Obesity: Evidence From a Birth Cohort Study

Abdullah A. Mamun1, Michael J. O'Callaghan2, Susanna M. Cramb1, Jake M. Najman1, Gail M. Williams1 and William Bor3

  1. 1Longitudinal Studies Unit, School of Population Health, University of Queensland, Brisbane, Queensland, Australia
  2. 2Child Development and Rehabilitation Services, Mater Children's Hospital, Brisbane, Queensland, Australia
  3. 3The Mater Centre for Service Research in Mental Health, Department of Psychiatry, University of Queensland, Brisbane, Queensland, Australia

Correspondence: Abdullah A. Mamun (mamun@sph.uq.edu.au)

Received 21 September 2007; Accepted 2 September 2008; Published online 15 January 2009.

Abstract

We examined whether behavioral problems in childhood and adolescence are associated with young adults' BMI and obesity, and tested whether childhood behavioral problems have a greater impact on young adults' obesity than adolescent behavioral problems. The data were from the Mater-University of Queensland Study of Pregnancy (MUSP) and Its Outcomes, a population-based birth cohort study commenced in Brisbane, Australia, in 1981. A subsample of 2,278 children for whom we had prospective information on their behavioral problems at ages 5 and 14 and measured BMI, and its categories (normal, overweight, and obese) at age 21 was chosen. Young adults who experienced behavioral problems at ages 5 or 14 had a greater average BMI and were more likely to be obese compared to young adults without behavioral problems at both ages. The childhood onset group was at greater risk of becoming obese by age 21 compared to the adolescent onset group (P = 0.04). These associations remained consistent after adjusting for a variety of potential covariates including maternal characteristics (i.e., demographics and life style), child dietary patterns, family meals, television (TV) watching, and participation in sports and exercise at 14 years. Childhood as well as persistent behavioral problems during childhood and adolescence predicts young adults' BMI and obesity. Although further studies are needed to confirm this association, there is a need for close monitoring of children presenting with behavioral problems.

Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates

Moral of the story: Eat less, exercise more. Do not try a new fad diet because it supposedly is the best for losing weight. Pick a diet that will make you eat healthier, less food and you will actually like and adhere to. The type of diet doesn't actually matter for losing weight.

Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates
Frank M. Sacks, M.D., George A. Bray, M.D., Vincent J. Carey, Ph.D., Steven R. Smith, M.D., Donna H. Ryan, M.D., Stephen D. Anton, Ph.D., Katherine McManus, M.S., R.D., Catherine M. Champagne, Ph.D., Louise M. Bishop, M.S., R.D., Nancy Laranjo, B.A., Meryl S. Leboff, M.D., Jennifer C. Rood, Ph.D., Lilian de Jonge, Ph.D., Frank L. Greenway, M.D., Catherine M. Loria, Ph.D., Eva Obarzanek, Ph.D., and Donald A. Williamson, Ph.D.


ABSTRACT

Background The possible advantage for weight loss of a diet that emphasizes protein, fat, or carbohydrates has not been established, and there are few studies that extend beyond 1 year.

Methods We randomly assigned 811 overweight adults to one of four diets; the targeted percentages of energy derived from fat, protein, and carbohydrates in the four diets were 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%; and 40, 25, and 35%. The diets consisted of similar foods and met guidelines for cardiovascular health. The participants were offered group and individual instructional sessions for 2 years. The primary outcome was the change in body weight after 2 years in two-by-two factorial comparisons of low fat versus high fat and average protein versus high protein and in the comparison of highest and lowest carbohydrate content.

Results At 6 months, participants assigned to each diet had lost an average of 6 kg, which represented 7% of their initial weight; they began to regain weight after 12 months. By 2 years, weight loss remained similar in those who were assigned to a diet with 15% protein and those assigned to a diet with 25% protein (3.0 and 3.6 kg, respectively); in those assigned to a diet with 20% fat and those assigned to a diet with 40% fat (3.3 kg for both groups); and in those assigned to a diet with 65% carbohydrates and those assigned to a diet with 35% carbohydrates (2.9 and 3.4 kg, respectively) (P>0.20 for all comparisons). Among the 80% of participants who completed the trial, the average weight loss was 4 kg; 14 to 15% of the participants had a reduction of at least 10% of their initial body weight. Satiety, hunger, satisfaction with the diet, and attendance at group sessions were similar for all diets; attendance was strongly associated with weight loss (0.2 kg per session attended). The diets improved lipid-related risk factors and fasting insulin levels.

Conclusions Reduced-calorie diets result in clinically meaningful weight loss regardless of which macronutrients they emphasize. (ClinicalTrials.gov number, NCT00072995 [ClinicalTrials.gov] .)

NEJM february 26, 2009 vol. 360 no. 9

Monday, March 23, 2009

Very low LDL and normal BP result in slowest progression of atherosclerosis

Moral of the story: 2 thing - Blood Pressure, LDL. Worry about those two things. Get them back to normal and you will go a long way towards preventing heart disease.

Heartwire - Clinical cardiology
Very low LDL and normal BP result in slowest progression of atherosclerosis
March 23, 2009 | Michael O'Riordan

Cleveland, OH - Patients with coronary artery disease (CAD) who reduce LDL cholesterol to very low levels and achieve a normal systolic blood pressure have the slowest progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS), a new study has shown [1]. The findings, according to investigators, support the need for intensive management of global risk in patients with CAD.

"What's happened in recent years with the advent of more potent statins and all the education done around that is that getting people to LDL goal is achieved fairly well," senior investigator Dr Steven Nissen (Cleveland Clinic, OH) told heartwire. "But getting people to dual goals is not done well around the country. We wanted to tell people that there really is some pretty good evidence here that if you get your blood pressure down to normal and your LDL down below 70, this is a disease that can not only be halted, but potentially can even regress."

The results of the study are published in the March 24, 2009 issue of the Journal of the American College of Cardiology.


Seven studies rolled into one

To clarify the relationship between LDL cholesterol and systolic blood pressure and their effects on coronary plaque progression, the researchers, led by Dr Adnan Chhatriwalla (Cleveland Clinic) studied 3437 patients with established CAD enrolled in seven clinical trials. The studies included REVERSAL, CAMELOT, ACTIVATE, ASTEROID, ILLUSTRATE, PERISCOPE, and STRADIVARIUS, a group of trials that investigated statins, acyl coenzyme A:cholesterol acyltransferase (ACAT) and cholesteryl ester transfer protein (CETP) inhibitors, rimonabant, ACE inhibitors, and calcium-channel blockers, among others.

Patients were stratified into four groups based on their average on-treatment LDL-cholesterol levels and systolic blood pressure:

  • LDL cholesterol <70 mg/dL and systolic blood pressure <120 mm Hg.
  • LDL cholesterol <70 mg/dL and systolic blood pressure >120 mm Hg.
  • LDL cholesterol >70 mg/dL and systolic blood pressure <120 mm Hg.
  • LDL cholesterol >70 mg/dL and systolic blood pressure >120 mmHg.

Changes in atheroma burden were monitored by IVUS, which was measured at baseline and at 18 to 24 months.

Patients with very low LDL-cholesterol levels and normal systolic blood pressure, group 1, had the least progression in percent atheroma volume (PAV) and total atheroma volume (TAV). In addition, these patients also had less frequent atheroma progression and more frequent regression. In patients with systolic blood pressure >120 mm Hg who still had very low LDL cholesterol levels, group 2, less progression of PAV and TAV was also observed.

"It really makes a big difference if you can get both down," said Nissen. "It's a big payoff for patients if physicians are diligent about getting LDL and blood pressure under control."

Among patients with LDL-cholesterol levels >70 mg/dL, normal systolic blood pressure was associated with no greater reduction in PAV or TAV, suggesting that lipid lowering has a larger impact than blood-pressure control on plaque progression, findings supported by recent clinical trials.

The findings challenge current treatment recommendations for hypertension, noted Nissen, and he recommends treating prehypertensive patients with coronary disease, those with pressures of 120 to 139 mm Hg systolic or 80 to 89 mm Hg diastolic. In the CAMELOT study, he points out, the calcium-channel blocker amlodipine decreased the risk of cardiovascular events in patients with CAD and normal blood pressure, as did the ACE inhibitor enalapril, but to a lesser extent.

"Remember that these are all people who have coronary artery disease," said Nissen. "These are not your typical primary-prevention patients with hypertension. They already have atherosclerotic disease in their coronaries. We think the evidence is pretty strong that if you already have plaques in your coronaries, you really to have a lower blood-pressure target. . . . Our IVUS data suggest that there is opportunity here to help patients."

Nissen admitted that the issue needs to be studied further and that the ongoing AQUARIUS study will assess changes in atherosclerotic disease progression with aliskiren (Tekturna, Novartis) when given in addition to standard therapy in CAD patients with prehypertension.


More data still needed

In an editorial accompanying the published study, Drs Jonathan Tobis and Alice Perlowski (University of California, Los Angeles) write that human and animal data make clear that a combination of aggressive lipid and blood-pressure control are necessary for a maximum attenuation of plaque progression, improved endothelial function, and reduced inflammation caused by oxidative stress [2].

Regarding the treatment of prehypertensive patients, Tobis and Perlowski write that a lack of data has contributed to a delayed acceptance of the need for drug therapy. In addition to AQUARIUS, the ongoing SPRINT, which is comparing intensive blood-pressure control (<120>130 mm Hg who have one additional risk factor, will help answer those questions.

The editorialists note that plaque progression/regression on IVUS is helpful in determining whether or not clinicians are helping their patients, but hard clinical end points are still needed, especially as they are shown to correspond with predictions based on the IVUS surrogates. Until then, "conclusions derived from these trials should be considered inferential, to be used as guides for future trials focused on clinical-outcomes measures," they write.

Asked about the polypill, Nissen told heartwire that he was not an initial fan, but with these and other data, he is starting to warm up to it. "The idea of having something that you go and get for $10 for three months that would control your blood pressure and your lipids, this study makes the case that it might make some sense."

New results about a polypill approach for primary prevention, combining a BP-lowering drug, a statin, and aspirin in a single pill, will be presented at the American College of Cardiology 2009 meeting next week.

Nissen reports receiving research support from AstraZeneca, Eli Lilly, Pfizer, Takeda, Sankyo, and Sanofi-Aventis and that he donates honoraria, consulting fees, and other payments directly to charity. Chhattriwalla reports no conflicts.
Sources
  1. Chhatriwalla AK, Nicholls SJ, Wang TH, et al. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol 2009; 53: 1110-1115.
  2. Tobis JM, Perlowski A. Atheroma volume by intravascular ultrasound as a surrogate for clinical endpoints. J Am Coll Cardiol 2009; 53: 1116-1118.

Friday, February 27, 2009

Green and Black Tea Consumption and Risk of Stroke. A Meta-Analysis

Moral of the story: Drinking black and green tea can help prevent a stroke. A meta-analysis is an analysis of all the literature on a single topic. This study found that taken all together, studies suggest that 3 cups of tea may be effective.

Green and Black Tea Consumption and Risk of Stroke. A Meta-Analysis

Lenore Arab PhD*;
Weiqing Liu MS; and David Elashoff PhD

From UCLA's School of Medicine, Los Angeles, Calif.

* To whom correspondence should be addressed. E-mail: Larab@ucla.edu.

Background and Purpose—Experimental models of stroke provide consistent evidence of smaller stroke volumes in animals ingesting tea components or tea extracts. To assess whether a similar association of black or green tea consumption with reduced risk is evident in human populations, we sought to identify and summarize all human clinical and observational data on tea and stroke.

Methods—We searched PubMed and Web of Science for all studies on stroke and tea consumption in humans with original data, including estimation or measurement of tea consumption and outcomes of fatal or nonfatal stroke. Data from 9 studies involving 4378 strokes among 194 965 individuals were pooled. The main outcome was the occurrence of fatal or nonfatal stroke. We tested for heterogeneity and calculated the summary effect estimate associated with consumption of ≥3 cups of tea (green or black) per day using random-effects and fixed-effects models for the homogeneous studies. Publication bias was also evaluated.

Results—Regardless of their country of origin, individuals consuming ≥3 cups of tea per day had a 21% lower risk of stroke than those consuming <1> 0.85). The proportion of heterogeneity not explained by chance alone was 23.8%.

Conclusions—Although a randomized clinical trial would be necessary to confirm the effect, this meta-analysis suggests that daily consumption of either green or black tea equaling 3 cups per day could prevent the onset of ischemic stroke.


Key words: black tea • Camelia sinensis • green tea • ischemic stroke • theophylline

Thursday, February 5, 2009

Breast cancer risk rapidly drops after stopping hormone therapy

Moral of the story: hormone replacement therapy is a better predictor of breast cancer incidence than mammography frequency. If you are on homone replacement therapy, get those mammo's! Both the Reuters article and NEJM journal abstract are included below.

Breast cancer risk rapidly drops after stopping hormone therapy
By Reuters Health
February 5, 2009


NEW YORK (Reuters Health), Feb 5 - The elevated risk of breast cancer seen with combined hormone therapy quickly declines after this treatment is stopped, according to a report in the New England Journal of Medicine for February 5.

The results of the Women's Health Initiative (WHI) trial released in 2002 linked use of estrogen plus progestin with increased breast cancer risk in postmenopausal women. Subsequently, use of this therapy in the U.S. decreased substantially accompanied by a drop in breast cancer rates. Whether the two trends were causally related, however, was unclear.

In fact, it was suspected that changes in the frequency of mammographic screening may have accounted for the apparent drop in breast cancer incidence.

To investigate, Dr. Marcia Stefanick, from Stanford University School of Medicine, California, and colleagues analyzed follow-up data from the WHI trial. Included in the postintervention phase of the trial were 7,854 women who had received conjugated equine estrogens (0.625 mg) plus medroxyprogesterone (2.5 mg) daily and 7,533 given placebo.

In the two years prior to the intervention phase of the study, fewer breast cancer diagnoses were seen in the combined hormone therapy group than in the placebo group. During the 5.6 years of intervention, however, the risk of breast cancer was 26% higher in the hormone therapy group.

After stopping hormone therapy, the risk of breast cancer fell rapidly. The annualized incidence decreased 43% within one year, and by two years it was essentially the same as in the placebo group.

Moreover, during this period, "differences in the frequency of mammography between the two groups were unchanged."

Overall, "This is very strong evidence that estrogen plus progestin causes breast cancer," Stefanick said in a statement. "You start women on hormones and within five years, their risk for breast cancer is clearly elevated. You stop the hormones and within one year, their risk is essentially back to normal. It's reasonably convincing cause-and-effect data."

Last Updated: 2009-02-04 17:00:12 -0400 (Reuters Health)

Related Reading

Current HRT use is associated with low-grade breast cancer tumors, October 22, 2008


N Engl J Med 2009;360:573-587

NEJM -- Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women

NEJM -- Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women

Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Rowan T. Chlebowski, M.D., Ph.D., Lewis H. Kuller, M.D., Dr.P.H., Ross L. Prentice, Ph.D., Marcia L. Stefanick, Ph.D., JoAnn E. Manson, M.D., Dr.P.H., Margery Gass, M.D., Aaron K. Aragaki, M.S., Judith K. Ockene, Ph.D., Dorothy S. Lane, M.D., Gloria E. Sarto, M.D., Aleksandar Rajkovic, M.D., Ph.D., Robert Schenken, M.D., Susan L. Hendrix, D.O., Peter M. Ravdin, M.D., Ph.D., Thomas E. Rohan, M.B., B.S., Ph.D., Shagufta Yasmeen, M.D., Garnet Anderson, Ph.D., for the WHI Investigators


ABSTRACT

Background Following the release of the 2002 report of the Women's Health Initiative (WHI) trial of estrogen plus progestin, the use of menopausal hormone therapy in the United States decreased substantially. Subsequently, the incidence of breast cancer also dropped, suggesting a cause-and-effect relation between hormone treatment and breast cancer. However, the cause of this decrease remains controversial.

Methods We analyzed the results of the WHI randomized clinical trial — in which one study group received 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate daily and another group received placebo — and examined temporal trends in breast-cancer diagnoses in the WHI observational-study cohort. Risk factors for breast cancer, frequency of mammography, and time-specific incidence of breast cancer were assessed in relation to combined hormone use.

Results In the clinical trial, there were fewer breast-cancer diagnoses in the group receiving estrogen plus progestin than in the placebo group in the initial 2 years of the study, but the number of diagnoses increased over the course of the 5.6-year intervention period. The elevated risk decreased rapidly after both groups stopped taking the study pills, despite a similar frequency of mammography. In the observational study, the incidence of breast cancer was initially about two times as high in the group receiving menopausal hormones as in the placebo group, but this difference in incidence decreased rapidly in about 2 years, coinciding with year-to-year reductions in combined hormone use. During this period, differences in the frequency of mammography between the two groups were unchanged.

Conclusions The increased risk of breast cancer associated with the use of estrogen plus progestin declined markedly soon after discontinuation of combined hormone therapy and was unrelated to changes in frequency of mammography.


Friday, January 23, 2009

F.D.A. Approves a Stem Cell Trial - And It Is Probably Not A Good Thing

Moral of the story: Playing with fire. This is not the trial that should be done first for embryonic stem cells. The backlash to poor results, which are likely given the data thus far, could be absolutely tremendous. This is yet another example of the FDA doing a shitty job at regulating pharma. Shame on Gera and shame on the FDA and shame on former President Bush.

F.D.A. Approves a Stem Cell Trial
http://www.nytimes.com/2009/01/23/business/23stem.html?ref=health

By ANDREW POLLACK
Published: January 23, 2009
In a research milestone, the federal government will allow the world’s first test in people of a therapy derived from human embryonic stem cells.

Federal drug regulators said that political considerations had no role in the decision. Nevertheless, the move coincided with the inauguration of President Obama, who has pledged to remove some of the financing restrictions placed on the field by President George W. Bush.
The clearance of the clinical trial — of a treatment for spinal cord injury — is to be announced Friday by Geron, the biotechnology company that first applied to the Food and Drug Administration to conduct the trial last March. The F.D.A. had first said no, asking for more data.
Thomas B. Okarma, Geron’s chief executive, said Thursday that he did not think that the Bush administration’s objections to embryonic stem cell research played a role in the F.D.A.’s delaying approval.
“We really have no evidence,” Dr. Okarma said, “that there was any political overhang.”
But others said they suspected it was more than a coincidence that approval was granted right after the new administration took office.
“I think this approval is directly tied to the change in administration,” said Robert N. Klein, the chairman of California’s $3 billion stem cell research program. He said he thought the Bush administration had pressured the F.D.A. to delay the trial.
Mr. Klein called the approval of the first human trial of this sort “an extraordinary benchmark.”
Stem cells derived from adults and fetuses are already being used in some clinical trials, but they generally have less versatility than embryonic stem cells in terms of what tissue types they can form.
The F.D.A. approval comes a little more than 10 years after the first human embryonic stem cells were isolated at the University of Wisconsin, in work financed by Geron.
Because the cells can turn into any type of cell in the body, the theory is they may one day be able to provide tissues to replace worn-out organs or nonfunctioning cells to treat diabetes, heart attacks and other diseases. The field is known as regenerative medicine.
The Bush administration restricted federal financing for research on embryonic stem cells because creation of the cells entails the destruction of human embryos.
Geron’s trial will involve 8 to 10 people with severe spinal cord injuries. The cells will be injected into the spinal cord at the injury site 7 to 14 days after the injury occurs, because there is evidence the therapy will not work for much older injuries.
The study is a so-called Phase I trial, aimed mainly at testing the safety of the therapy. There would still be years of testing and many hurdles to overcome before the treatment would become routinely available to patients.
Geron, which is based in Menlo Park, Calif., said that it had identified up to seven medical centers for the trial but that those sites must first get permission from their own internal review boards to participate.
Even as some researchers hailed the onset of clinical trials, others expressed trepidation that if the therapy proves unsafe — or even if it is safe but does not work — it could cause a backlash that would set the field back for years.
“It would be a disaster, a nightmare, if we ran into these kinds of problems in this very first trial,” said Dr. John A. Kessler, the chairman of neurology and director of the stem cell institute at Northwestern University.
Dr. Kessler, whose own daughter was paralyzed from the waist down in a skiing accident, said he thought Geron’s therapy was not the ideal candidate for the first trial. He said results showing the therapy worked in moderately injured animals might not apply to more seriously injured people.
“We really want the best trial to be done for this first trial, and this might not be it,” he said.
Dr. Okarma of Geron emphasized that the purpose of the first trial was safety, so that lack of efficacy should not be a problem. While researchers will also look for signs the treatment works, he said, the best that could be hoped for would be some slight restoration of function that could then be enhanced through physical therapy.
“We don’t expect to take someone who is completely paralyzed from the waist down and have them dance six months later,” he said. If the first trial shows safety, the company would then hope to test higher doses of cells and treat patients with less severe injuries, he said.
Geron’s therapy involves using various growth factors to turn embryonic stem cells into precursors of neural support cells called oligodendrocytes, which are then injected into the spinal cord at the site of the injury.
The hope is that the injected cells will help repair the insulation, known as myelin, around nerve cells, restoring the ability of some nerve cells to carry signals. There is also some hope that growth factors produced by the injected cells will spur damaged nerve cells to regenerate.
The therapy was developed in collaboration with Hans Keirstead of the University of California, Irvine. He has shown videos of paralyzed rats that were able to walk again, albeit imperfectly, after receiving the therapy. Those videos helped persuade California voters to approve the $3 billion stem cell research program in 2004.
The main safety concern is that if raw embryonic cells are put into the body, they can form tumors. Even though most such tumors do not spread like other cancers, any unwanted growth in the spinal cord can further damage nerves.
“It’s not ready for prime time, at least not in my mind, until we can be assured that the transplanted stem cells have completely lost the capacity for tumorogenicity,” said Dr. Steven Goldman, chairman of neurology at the University of Rochester. He was a member a committee convened by the F.D.A. last April to examine the safety aspects of trials using therapies from embryonic stem cells.
Dr. Okarma said Geron had done numerous studies showing that its cells did not contain residual embryonic cells and did not form tumors in animals even after a year. It submitted 22,000 pages of data to the F.D.A., perhaps the largest application ever for permission to begin a clinical trial.
The embryonic stem cell line used by Geron is one of the oldest ones and was therefore eligible for federal financing under the Bush administration’s policy, Dr. Okarma said.
Nevertheless, Geron paid for its own work, spending $45 million to prepare its F.D.A. application.
Geron, which was formed in 1990 as an antiaging company, is still in the development stage and is not yet profitable, having lost about $500 million since its inception. Besides working on stem cells, it is testing drugs for cancer that influence telomeres, the caps on the ends of chromosomes that help control the aging of cells. Geron’s market value is about $400 million.
While the Bush administration’s policy did not impede the company’s application at the F.D.A., Dr. Okarma said, it did slow progress for the field in general by making it hard for academics to do research.
“It is the private sector that has kept the technology alive so that it can see the light of day in a clinical trial,” he said.
Mr. Klein of the California stem cell program said he thought the next trial might be of a treatment for macular degeneration, an eye disease, that is being developed in Britain.
In the last couple of years, some attention has turned away from embryonic stem cells to a newer technique that allows a patient’s own skin cells to be turned into a cell resembling such embryonic cells.
That might do away with the need for embryos. And the resulting tissue made from those cells would match the patient, doing away with the need for immune suppression to prevent rejection of the transplant. Geron said its trial would require only temporary use of low doses of immune-suppressing drugs.
But the newer technique involves putting genes into the skin cells using viruses, which also raises a risk of cancer.